Elucidating the Genomic and Proteomic Parameters for Restenotic Patients
碩士 === 中國醫藥大學 === 生物科技學系 === 96 === Percutaneous transluminal coronary angioplasty is often applicated for clinical treatment of stenosis after atherosclerosis;however, there are about 30-50% patients who will have restenosis within 6 months. Even using the stents, there are also 10-30% patients who...
Main Authors: | Hsiang-Tien Huang, 黃湘恬 |
---|---|
Other Authors: | 吳介信 |
Format: | Others |
Language: | zh-TW |
Published: |
2008
|
Online Access: | http://ndltd.ncl.edu.tw/handle/06194148742021701062 |
Similar Items
-
Quantification of Adventitial Vasa Vasorum Vascularization in Double-injury Restenotic Arteries
by: Meng Ye, et al.
Published: (2015-01-01) -
Nanostructured ultra-thin patches for ultrasound-modulated delivery of anti-restenotic drug
by: Vannozzi L, et al.
Published: (2015-12-01) -
The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis
by: Hideki Kushima, et al.
Published: (2017-10-01) -
A comparison between drug-eluting stent implantation and drug-coated balloon angioplasty in patients with left main bifurcation in-stent restenotic lesions
by: Hyungdon Kook, et al.
Published: (2020-02-01) -
Anti-Restenotic Roles of Dihydroaustrasulfone Alcohol Involved in Inhibiting PDGF-BB-Stimulated Proliferation and Migration of Vascular Smooth Muscle Cells
by: Pei-Chuan Li, et al.
Published: (2015-05-01)